Kirsten A. Aaldering
Roermond, LI, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Complete responders in patients with HER2-positive metastatic breast cancer: a real-world SONABRE study.
Journal: Breast (Edinburgh, Scotland)
Published: July 28, 2025
Receptor Discordance During the Treatment Course of Patients With Metastatic Breast Cancer: Results From the SONABRE Registry.
Journal: Clinical breast cancer
Published: April 24, 2025
Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry.
Journal: Breast cancer research and treatment
Published: September 04, 2023
The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE registry.
Journal: Breast cancer research and treatment
Published: July 11, 2023
Trastuzumab Resistance in Patients With HER2-Positive Advanced Breast Cancer: Results From the SONABRE Registry.
Journal: Clinical breast cancer
Published: April 03, 2023
Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry.
Journal: Breast cancer research and treatment
Published: October 17, 2022
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2- metastatic breast cancer: an observational study of the SONABRE Registry.
Journal: The Lancet regional health. Europe
Published: October 11, 2022
The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry.
Journal: Breast cancer research and treatment
Published: October 12, 2021
The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE Registry.
Journal: International journal of cancer
Published: April 19, 2021
Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry.
Journal: Breast cancer research and treatment
Published: January 19, 2021
An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry.
Journal: Acta oncologica (Stockholm, Sweden)
Published: June 17, 2020
The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry.
Journal: Acta oncologica (Stockholm, Sweden)
Published: October 05, 2019
Last Updated: 09/26/2026